Major Regulatory Milestone in MM: In response to an application by I2TEAMM and IMFmyeloma, the European Medicines Agency has officially endorsed MRD as an early endpoint in clinical trials for Myeloma. This marks a transformative step forward in drug development !! @vincentrk.bsky.social
26.06.2025 04:09 β π 3 π 2 π¬ 0 π 0
#ASH24 myeloma, gene expression review of genes in 17p del patients only PKMYT1 is over expressed and KO is lethal, drug exist that seems to be uniquely effective. High potential for benefit observation from @nikhilmunshi.bsky.social lab
09.12.2024 19:01 β π 10 π 2 π¬ 1 π 0
An interesting paper in Blood by Dr. Samur suggesting that the cell that eventually becomes myeloma first acquires extra chromosome in 2nd decade of life and becomes fully hyperdiploid by 3rd. Implication for many cancers. @pedalheadphx.bsky.social @auclairdan.bsky.social @szusmani.bsky.social
23.11.2024 16:54 β π 23 π 8 π¬ 3 π 2
Welcoming all myeloma colleagues and science and medicine interested to this platform and group ! @myeloma-society.bsky.social; @imfmyeloma.bsky.social;
23.11.2024 00:03 β π 6 π 0 π¬ 2 π 0
Entrepreneur
Costplusdrugs.com
Heme Chief at Stanford. Physician Scientist studying myeloid malignancies. Views my own.
VP of Oncology Global Medical Affairs at Johnson & Johnson focused on bringing new treatment options for patients with cancer. Posts shared are my own. π¬π§πΊπΈπ³οΈβπ
Professor of Medicine, Harvard Medical School
Director of Geriatric Diabetes Program at Joslin Diabetes Center
Geriatrician, Beth Israel Deaconess Medical Center
Editor in Chief, Blood Cancer Journal; Professor, Mayo Clinic; Associate Editor, Mayo Clinic Proceedings; Oncologist, Cancer Research, Myeloma.
π¨π¦ boiling in the Arizona desert and not riding my bikes enough. Cancer researcher focused on multiple myeloma and clinical genomics at TGen, part of City of Hope. Creator of MyelomaSky and Sequencing Tech feeds. Director, Collaborative Sequencing Center
As quoted in the Manchester Evening News. I hope the fame doesnβt destroy me.
Haemato-oncologist and myeloma researcher; genetics, imaging and more for patient-centric care. Vice-chair UK NCRI Myeloma Trials. EHA European Affairs. Interested in access and HTA. Academic nomad.
Physician scientist UCLA --> BWH <--> DFCI. Myeloma, CAR-T, CHIP, MDS. LA sports fan stuck in Boston.
Hematologist, involved in preclinical and clinical research in plasma cell disorders, MmGTr, EMN, BMSG board, IMWG member, Istinye University Ankara Liv Hospital TΓΌrkiye
Assistant Professor at Mount Sinai, NY. Integrative cancer genomics, precision oncology, multiple myeloma.
http://laganalab.org
Hematologist/Oncologist at the University of Pennsylvania with clinical and research focus on multiple myeloma and related plasma cell disorders.
Physician-Scientist | Assistant Professor at Mayo Clinic | Hematologic Malignancies | Multiple Myeloma | Computational Biology
Assistant Professor at Fred Hutch Cancer Center (Seattle, WA, USA) specializing in multiple myeloma #MMsm and CAR-T therapy.
My research focus: improving the patient experience in myeloma.
COI: https://coi.asco.org/share/VU2-FHC3/Rahul%20Banerjee
Professor at the NYU School of Medicine (https://yanailab.org/). Founder and Director of the Night Science Institute (https://night-science.org/). Co-host of the 'Night Science Podcast' https://podcasts.apple.com/us/podcast/night-science/id1563415749
Blood cancer translational scientist with a special love for #myeloma, animals and nature friend | Opinions are my own #MyelomaSky #HemeSky
Physician Scientist. Interested in early detection and interception in myeloma.